Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Non-Erosive Reflux Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Non-Erosive Reflux Disease. Displaying page 1 of 1.
    EudraCT Number: 2009-017229-20 Sponsor Protocol Number: KCT 27/2009 – PAN-STAR/PL Start Date*: 2010-06-24
    Sponsor Name:KRKA-POLSKA Sp. z o.o.
    Full Title: Efficacy and safety of PANtoprazole in the treatment and SympTom relief in patients with gAstRoesophageal reflux disease (GERD) – PAN-STAR
    Medical condition: gastroesophageal reflux disease (GERD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066874 Gastroesophageal reflux disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004856-11 Sponsor Protocol Number: BY1023/DE004 Start Date*: 2006-07-12
    Sponsor Name:ALTANA Pharma AG
    Full Title: Symptom reduction in hospitalized patients suffering from symptomatic non-erosive or erosive gastroesophageal reflux disease treated with pantoprazole 20 or 40 mg o.d. for 7 days
    Medical condition: Symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017885 Gastrooesophageal reflux disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002779-42 Sponsor Protocol Number: BY359/M3-201 Start Date*: 2006-11-06
    Sponsor Name:ALTANA Pharma AG
    Full Title: Symptom relief and tolerability of Soraprazan 20 mg qd and Soraprazan 10 mg qd compared to Esomeprazole 20 mg qd in patients with non-erosive gastroesophageal reflux disease (NERD)
    Medical condition: Non-Erosive Gastroesophageal Reflux Disease (NERD) as confirmed by endoscopy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018203 GERD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-002031-92 Sponsor Protocol Number: EX0307 Start Date*: Information not available in EudraCT
    Sponsor Name:Otto-von-Guericke University
    Full Title: Proliferation and differentiation markers, involved in erosive and non-erosive reflux esophagitis, Barrett´s esophagus and esophageal adenocarcinoma.
    Medical condition: Dyspeptic Symptoms GERD (gastroesophageal reflux disease), NERD (non erosive reflux disease), ERD (erosive reflux disease), Barretts esophagus, Adeno-CA of the esophagus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017885 Gastrooesophageal reflux disease PT
    9.1 10004137 Barrett's oesophagus PT
    9.1 10001173 Adenocarcinoma of esophagus LLT
    9.1 10013949 Dyspeptic signs and symptoms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001680-72 Sponsor Protocol Number: TAK-390MR_206 Start Date*: 2012-10-09
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Relief of Heartburn, in Adolescen...
    Medical condition: Heartburn in Adolescent subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10066874 Gastroesophageal reflux disease LLT
    14.1 100000004856 10019326 Heartburn LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004882-32 Sponsor Protocol Number: BY1023/NL511 Start Date*: 2006-11-20
    Sponsor Name:ALTANA Pharma bv
    Full Title: Evaluation of clinical endpoints for treatment-induced changes in GERD-related symptoms
    Medical condition: gastroesophageal reflux disease (GERD) or Non Erosive Reflux Disease (NERD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017885 Gastrooesophageal reflux disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-004806-25 Sponsor Protocol Number: BY1023/M3-339 Start Date*: 2005-04-25
    Sponsor Name:ALTANA Pharma AG
    Full Title: Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. ove...
    Medical condition: Gastroesophageal reflux disease
    Disease: Version SOC Term Classification Code Term Level
    5.0 10038263 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-005203-32 Sponsor Protocol Number: NERONE Start Date*: 2012-04-17
    Sponsor Name:UNIVERSITA' CAMPUS BIOMEDICO
    Full Title: A prospective, multicenter, open-label, patients with non-erosive gastroesophageal reflux disease (NERD) non-responders to therapy with PPIs
    Medical condition: non-erosive gastroesophageal reflux disease and apparently resistant to medical therapy with proton pump inhibitors
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:51:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA